Tyrosine kinase inhibitors

Details for Australian Patent Application No. 2003261415 (hide)

Owner Merck & Co., Inc.

Inventors Lindsley, Craig W.; Beshore, Douglas C.; Bergman, Jeffrey M.; Dinsmore, Christopher J.

Agent Spruson & Ferguson

Pub. Number AU-B-2003261415

PCT Number PCT/US03/24643

PCT Pub. Number WO2004/014851

Priority 60/402,478 09.08.02 US

Filing date 5 August 2003

Wipo publication date 25 February 2004

Acceptance publication date 30 July 2009

International Classifications

C07D 487/10 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 31/138 (2006.01) - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine

A61K 31/337 (2006.01) - having four-membered rings, e.g. taxol

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/404 (2006.01)

A61K 31/407 (2006.01) - condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine

A61K 31/438 (2006.01) - the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/4465 (2006.01) - only substituted in position 4

A61K 31/4535 (2006.01)

A61K 31/454 (2006.01)

A61K 31/4545 (2006.01)

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61K 31/5377 (2006.01)

A61K 31/541 (2006.01) - Non-condensed thiazines containing further heterocyclic rings

A61K 31/547 (2006.01) - spiro-condensed or forming part of bridged ring systems

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61K 31/551 (2006.01) - having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep

A61K 31/553 (2006.01) - having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 1/04 Drugs for disorders of the alimentary tract or the digestive system

Event Publications

20 November 2003 Complete Application Filed

  Priority application(s): 60/402,478 09.08.02 US

8 April 2004 Application Open to Public Inspection

  Published as AU-B-2003261415

30 July 2009 Application Accepted

  Published as AU-B-2003261415

24 September 2009 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 25 Aug 2009. Address for service in Australia - Spruson & Ferguson Level 35 St Martins Tower 31 Market Street Sydney NSW 2000

14 January 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 25 Aug 2009

21 January 2010 Standard Patent Sealed

11 February 2010 Amendment Made

  The nature of the amendment is: Amend the patentee name from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

11 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003261416-DEVICES, SYSTEMS, AND METHODS FOR MEDIATED RULE-BASED TRANSLATION OF SYSTEM CONFIGURATION INFORMATION

2003261414-USE OF SURFACTANTS TO SOLUBILIZE WATER-INSOLUBLE SOLIDS IN BEVERAGES